Spots Global Cancer Trial Database for bexxar
Every month we try and update this database with for bexxar cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab | NCT00240578 | Lymphoma, Non-H... | 18 Years - | GlaxoSmithKline | ||
| Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant | NCT00434629 | B-cell Lymphoma Non-Hodgkin's L... | Bexxar | 18 Years - 75 Years | University of Pennsylvania | |
| Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab | NCT00996593 | Lymphoma, Non-H... | Anti-B1 Antibod... | 18 Years - | GlaxoSmithKline | |
| Expanded Access Study of Iodine-131 Anti-B1 Antibody | NCT00022958 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | NCT00992992 | Lymphoma, Mantl... | Tositumomab and... | 18 Years - | GlaxoSmithKline | |
| Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma | NCT01389076 | Follicular Lymp... | Bexxar Low Dose Methot... | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma | NCT00315731 | Lymphoma, Folli... | Follicular Lymp... | 18 Years - | GlaxoSmithKline | |
| Expanded Access Study of Iodine-131 Anti-B1 Antibody | NCT00022958 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | NCT00992992 | Lymphoma, Mantl... | Tositumomab and... | 18 Years - | GlaxoSmithKline | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement | NCT00992758 | Lymphoma, Non-H... | Iodine-131 Anti... | 18 Years - | GlaxoSmithKline | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia | NCT00022880 | Chronic Lymphoc... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma | NCT00577629 | Lymphoma, B-Cel... | cyclophosphamid... etoposide rituximab cytarabine doxorubicin tositumomab | 18 Years - | Duke University | |
| Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant | NCT00434629 | B-cell Lymphoma Non-Hodgkin's L... | Bexxar | 18 Years - 75 Years | University of Pennsylvania | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement | NCT00992758 | Lymphoma, Non-H... | Iodine-131 Anti... | 18 Years - | GlaxoSmithKline | |
| Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies | NCT01224821 | Lymphoma, Non-H... | Tositumomab (An... | 18 Years - | GlaxoSmithKline | |
| Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab | NCT00996593 | Lymphoma, Non-H... | Anti-B1 Antibod... | 18 Years - | GlaxoSmithKline | |
| Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab | NCT00240591 | Lymphoma, Non-H... | 18 Years - | GlaxoSmithKline | ||
| Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma | NCT00996996 | Lymphoma, Non-H... | Tositumomab and... | 18 Years - | GlaxoSmithKline | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP | NCT00022932 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - 80 Years | Corixa Corporation | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma | NCT00022893 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma | NCT00996996 | Lymphoma, Non-H... | Tositumomab and... | 18 Years - | GlaxoSmithKline | |
| Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab | NCT00240591 | Lymphoma, Non-H... | 18 Years - | GlaxoSmithKline | ||
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | NCT00022945 | Mantle Cell Lym... | Iodine-131 Anti... Cyclophosphamid... | 18 Years - | Corixa Corporation | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement | NCT00022906 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement | NCT00022906 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen | NCT00319332 | Lymphoma, Small... Lymphoma, Large... Lymphoma, Folli... Lymphoma, Non-H... | Ibritumomab Tiu... Iodine I 131 To... | 18 Years - | GlaxoSmithKline | |
| Phase 2 Study of Bexxar in Relapsed/Refractory DLCL | NCT00490009 | Lymphoma | Bexxar Acetaminophen Diphenhydramine Potassium Iodid... | 19 Years - | Stanford University | |
| Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma | NCT00577629 | Lymphoma, B-Cel... | cyclophosphamid... etoposide rituximab cytarabine doxorubicin tositumomab | 18 Years - | Duke University | |
| Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma | NCT00268983 | Lymphoma, Non-H... | Tositumomab and... Rituximab | 18 Years - | GlaxoSmithKline | |
| Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma | NCT00577629 | Lymphoma, B-Cel... | cyclophosphamid... etoposide rituximab cytarabine doxorubicin tositumomab | 18 Years - | Duke University | |
| Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma | NCT00240565 | Lymphoma, Non-H... | Tositumomab 450... Tositumomab 35 ... | 18 Years - | GlaxoSmithKline | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma | NCT00022893 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab | NCT00062894 | Non-Hodgkin's L... | Iodine I 131 To... | 18 Years - | GlaxoSmithKline | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia | NCT00022880 | Chronic Lymphoc... | Iodine-131 Anti... | 18 Years - | Corixa Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
